About Us
Genomenon is a genomics intelligence company in the lead position to be the first to curate the entire human genome. Our team is dedicated to improving the quality of patients’ lives by characterizing the genomic drivers of genetic disease and cancer. Genomenon's curation process emphasizes the clinical relevance of genetic findings, ensuring that curated data directly supports accurate diagnosis and effective treatment decisions.
Blending the power of AI with the precision of genomic expertise, Genomenon simplifies complex genetic data into actionable insights for patient diagnosis and precision medicine development.
Genomenon, a name signifying “born out of need” in ancient Greek, perfectly encapsulates the genesis of our journey.
In his clinical practice and genomic research, co-founder Dr. Mark Kiel was frustrated with the painfully slow and time-consuming process of manual curation. He was also well aware of the diagnostic odyssey that thousands of rare disease patients and families face as he and his twin brother had hypodontia, or missing adult teeth, in their youth. Living with a rare condition as a child focused Mark’s attention on genetics and his desire to make an impact on rare diseases.
Genomenon was founded in 2014 to address this pressing need for faster, more comprehensive variant interpretation by combining expert curation with unique machine-learning methods designed to keep up with the pace of new publications and present the most relevant information to researchers.
Today, Genomenon empowers scientists, researchers and clinicians at pharmaceutical companies, clinical labs, and universities to more thoroughly understand diseases at a molecular level.
Genomenon is headquartered in Ann Arbor, Michigan.
Expertise in Genomics
Our team of genetic scientists and expert curators review scientific publications and leverage our genomics focused artificial intelligence to analyze and interpret vast amounts of genomic data. This expertise enables us to provide unparalleled genomic insights that support patient diagnosis and precision medicine development.
With Genomenon's software, data, and services, users can simplify complex genetic data into actionable insights, driving advancements in clinical research and precision medicine.
Our Offerings Include
Never Miss a
Diagnosis
Accelerate variant interpretation and improve diagnostic yield through rapid genomic literature search and comprehensive, curated genomic insights.
Inform Your Drug Program
Gain rapid literature-derived real world evidence to inform rare disease efforts from discovery through commercialization.
Every accolade is a testament to our team and our mission to make genomic information actionable
Our Leadership Team
Working together to make genomic information actionable.
Dr. Mark Kiel is the co-founder and chief scientific officer at Genomenon, where he oversees the company's scientific direction and product development. Mark received his MD/PhD in Clinical Pathology at the University of Michigan. He founded Genomenon to address the challenge of connecting researchers with evidence in the literature to help diagnose and treat patients with rare genetic diseases and cancer.
As CTO, Jonathan Eads spearheads Genomenon's software development team leading the technical vision and implementation for the company technologies, including its AI strategy. He brings 25 years of experience in genomics, drug discovery, bioinformatics, and AI/ML software application development, with extensive experience building and leading engineering teams to deliver operational excellence.
Our Core Values
Customer &
Patient Centric
We put customers and patients first in everything that we do.
Always Learning
We approach challenges with curiosity & a growth mindset to imagine what can be, not what is.
Data Driven
We ask questions and look to the evidence for answers.
Humbly
Confident
We have confidence in who we are, where we're going, and how we're getting there.
True
Grit
We embody passion, persistence, and aren't afraid of hard work.
